Market Place
Sourcing Support
Blade Therapeutics CEO, CFO appear to depart amid `transition` after nixed SPAC
15 Dec 2022 //
ENDPTS
Blade Presents Analyses from PI & Preclinical Studies of Cudetaxestat at ERSI
04 Sep 2022 //
BUSINESSWIRE
Blade Therapeutics to Participate in Panel Discussion at BTIG Biotech Conference
01 Aug 2022 //
BUSINESSWIRE
Blade Therapeutics` SPAC merger is cancelled
14 Jun 2022 //
FIERCEBIOTECH
BAC and Blade Therapeutics Postpone Extraordinary Meeting of Shareholders
02 Jun 2022 //
PRNEWSWIRE
Blade Tx Presents PC Data on Differentiating Characteristics of Cudetaxestat
18 May 2022 //
BUSINESSWIRE
Blade Tx Presents Data from PI and PC Studies of Cudetaxestat at ATS
16 May 2022 //
BUSINESSWIRE
BAC and Blade Tx Announce Effectiveness of Registration Statement on Form S-4
09 May 2022 //
PRNEWSWIRE
Biotech Acquisition Co. Tells Filing of 1st Amendment to Registration Statement
04 Apr 2022 //
PRNEWSWIRE
Blade Therapeutics Announces Feedback from FDA on End-of-Phase 1 Data Package
04 Apr 2022 //
BUSINESSWIRE
Blade Tx to Present Data from Preclinical and Phase 1 Studies of Cudetaxestat
24 Mar 2022 //
BUSINESSWIRE
Blade Therapeutics to Participate in Upcoming Investor Conferences
07 Mar 2022 //
BUSINESSWIRE
Blade Tx Completes Phase 1 Study Evaluating Co-Administration of Cudetaxestat
12 Jan 2022 //
BUSINESSWIRE
Blade announces positive results from phase 1 study of cudetaxestat in IPF
02 Dec 2021 //
PHARMABIZ
Blade Appoints Bassem Elmankabadi as Senior VP of Clinical Development
18 Nov 2021 //
BUSINESSWIRE
Blade runs to Wall St. at $353M SPAC deal for 2 trials in 2022
09 Nov 2021 //
BIOSPACE
GSK brings Johns Hopkins prof and Blade co-founder on board; & more
27 Oct 2021 //
ENDPTS
Blade Therapeutics Begins Additional Phase 1 Study of Cudetaxestat for IPF
18 Oct 2021 //
BUSINESSWIRE
FDA Grants ODD to Blade Therapeutics` Cudetaxestat for Systemic Sclerosis
14 Oct 2021 //
BUSINESSWIRE
Blade to Publish PC Data for Neuroprotective Effects of Calpain Inhibitor
07 Oct 2021 //
BUSINESSWIRE
Blade shows +ve Data from Drug-Drug Interaction Study of Cudetaxesta in IPF
20 Sep 2021 //
BUSINESSWIRE
Blade finishes Enrollment for Phase 2 Study in Patients With COVID-19 Pneumonia
14 Sep 2020 //
BIOSPACE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.